Summary
27.74 -0.01(-0.02%)06/21/2024
Pfizer Inc. (PFE)
Pfizer Inc. (PFE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.02 | 0.73 | -2.99 | 0.25 | -2.01 | -28.70 | -23.82 | 15,607.47 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 27.74 | |
| Open | 27.77 | |
| High | 27.89 | |
| Low | 27.56 | |
| Volume | 27,631,375 | |
| Change | -0.00 | |
| Change % | -0.02 | |
| Avg Volume (20 Days) | 26,223,603 | |
| Volume/Avg Volume (20 Days) Ratio | 1.05 | |
| 52 Week Range | 25.20 - 39.24 | |
| Price vs 52 Week High | -29.32% | |
| Price vs 52 Week Low | 10.06% | |
| Range | -0.13 | |
| Gap Up/Down | -0.19 | |
Fundamentals | ||
| Market Capitalization (Mln) | 158,835 | |
| EBIDTA | 9,621,000,192 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.2560 | |
| WallStreet Target Price | 31.37 | |
| Book Value | 16.2840 | |
| Earnings Per Share | -0.0500 | |
| EPS Estimate Current Quarter | 0.5200 | |
| EPS Estimate Next Quarter | 0.4400 | |
| EPS Estimate Current Year | 2.3600 | |
| EPS Estimate Next Year | 2.7600 | |
| Diluted EPS (TTM) | -0.0500 | |
| Revenues | ||
| Profit Marging | -0.0056 | |
| Operating Marging (TTM) | 0.3163 | |
| Return on asset (TTM) | 0.0093 | |
| Return on equity (TTM) | -0.0026 | |
| Revenue TTM | 54,889,000,960 | |
| Revenue per share TTM | 9.7170 | |
| Quarterly Revenue Growth (YOY) | -0.1950 | |
| Quarterly Earnings Growth (YOY) | -0.4340 | |
| Gross Profit (TTM) | 66,233,000,000 | |
| Dividends | ||
| Dividend Share | 1.6500 | |
| Dividend Yield | 0.0600 | |
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 11.6686 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.6451 | |
| Revenue Enterprise Value | 3.4975 | |
| EBITDA Enterprise Value | 21.4072 | |
| Shares | ||
| Shares Outstanding | 5,666,590,208 | |
| Shares Float | 5,657,809,679 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.05 | |
| Institutions (%) | 70.15 | |
06/22 06:03 EST - fool.com
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
Pfizer has a lot of new drugs on the market, but its stock has been beaten down. Johnson & Johnson stock is down even though both its medical technology and pharmaceutical businesses reported significant gains this year.
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
Pfizer has a lot of new drugs on the market, but its stock has been beaten down. Johnson & Johnson stock is down even though both its medical technology and pharmaceutical businesses reported significant gains this year.
06/21 10:05 EST - zacks.com
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
06/20 19:18 EST - youtube.com
Palantir and Pfizer CEOs meet U.S. Senators to press for Israel support and hostage release
Alex Karp, Palantir CEO and Albert Bourla, Pfizer CEO, sit down with CNBC's Sara Eisen to discuss the Israel-Hamas War and antisemitism.
Palantir and Pfizer CEOs meet U.S. Senators to press for Israel support and hostage release
Alex Karp, Palantir CEO and Albert Bourla, Pfizer CEO, sit down with CNBC's Sara Eisen to discuss the Israel-Hamas War and antisemitism.
06/20 12:43 EST - investorplace.com
Skip Meme Mania: 3 Undervalued Blue-Chip Stocks for Steady Returns
Long-term investing is possibly among the most boring things. After identifying a quality stock, it's a matter of holding with patience.
Skip Meme Mania: 3 Undervalued Blue-Chip Stocks for Steady Returns
Long-term investing is possibly among the most boring things. After identifying a quality stock, it's a matter of holding with patience.
06/20 12:05 EST - youtube.com
Pfizer & Palantir CEOs speak out on Israel-Hamas war and antisemitism
Alex Karp, Palantir CEO and Albert Bourla, Pfizer CEO, sit down with CNBC's Sara Eisen to discuss the Israel-Hamas War and antisemitism.
Pfizer & Palantir CEOs speak out on Israel-Hamas war and antisemitism
Alex Karp, Palantir CEO and Albert Bourla, Pfizer CEO, sit down with CNBC's Sara Eisen to discuss the Israel-Hamas War and antisemitism.
06/20 09:00 EST - seekingalpha.com
Dividend Harvesting Portfolio Week 172: $17,200 Allocated, $1,532.26 In Projected Dividends
This week, I added to my positions in CSCO, PFE, and UTF. In the 2nd week of June, the Dividend Harvesting Portfolio generated $21.73 of dividend income. The Dividend Harvesting Portfolio has already generated 65.31% of the total dividend income from 2023.
Dividend Harvesting Portfolio Week 172: $17,200 Allocated, $1,532.26 In Projected Dividends
This week, I added to my positions in CSCO, PFE, and UTF. In the 2nd week of June, the Dividend Harvesting Portfolio generated $21.73 of dividend income. The Dividend Harvesting Portfolio has already generated 65.31% of the total dividend income from 2023.
06/20 08:00 EST - investorplace.com
3 Underrated Dividend Stock Machines to Turbocharge Your Income
You can make your money work for you by investing in the right stocks. One of them is dividend stocks but you do not want to bet your money on companies that have irregular dividend payments or are less reliable.
3 Underrated Dividend Stock Machines to Turbocharge Your Income
You can make your money work for you by investing in the right stocks. One of them is dividend stocks but you do not want to bet your money on companies that have irregular dividend payments or are less reliable.
06/20 07:30 EST - investorplace.com
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
While investing, the focus is on the top blue-chip stocks to buy that offer growth with stability. It is vital to comprehend the fundamentals that characterize these superior stocks.
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
While investing, the focus is on the top blue-chip stocks to buy that offer growth with stability. It is vital to comprehend the fundamentals that characterize these superior stocks.
06/19 05:49 EST - seekingalpha.com
Readers Identify 29 Ideal May Dividend Buys
Prior to May 31, 2024, my Readers mentioned 37 equities in their comments on my articles. Some bad-news investments (Rogues) mixed with (mostly) Favorites. Thus, readers commented about the ReFa/Ro. Ten analyst-target-estimated top net gain ReFa/Ro: T, VZ, PFE, BEN, EPR, CVX, FBY, TTE, ORC, and RC averaged 23.58% net gains from reader data collected 6/14/24. Ten analyst-target-augured May top price upside reader faves & rogues (ReFa/Ro) were: O, ORI, EPR, T, VZ, PFE, BEN, RC, CVX & TTE, boasting a 16.05% average target price upside estimate.
Readers Identify 29 Ideal May Dividend Buys
Prior to May 31, 2024, my Readers mentioned 37 equities in their comments on my articles. Some bad-news investments (Rogues) mixed with (mostly) Favorites. Thus, readers commented about the ReFa/Ro. Ten analyst-target-estimated top net gain ReFa/Ro: T, VZ, PFE, BEN, EPR, CVX, FBY, TTE, ORC, and RC averaged 23.58% net gains from reader data collected 6/14/24. Ten analyst-target-augured May top price upside reader faves & rogues (ReFa/Ro) were: O, ORI, EPR, T, VZ, PFE, BEN, RC, CVX & TTE, boasting a 16.05% average target price upside estimate.
06/18 18:51 EST - zacks.com
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Pfizer (PFE) closed at $27.41, marking a +1.59% move from the previous day.
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Pfizer (PFE) closed at $27.41, marking a +1.59% move from the previous day.
06/18 13:25 EST - barrons.com
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
Pfizer currently dominates the market for pneumococcal vaccines. Merck aims to change that.
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
Pfizer currently dominates the market for pneumococcal vaccines. Merck aims to change that.
06/18 10:00 EST - fool.com
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
High-yield dividend stocks can be potent long-term value creators. Pharma titans Pfizer and Bristol Myers Squibb sport two of the highest yields within their peer group.
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
High-yield dividend stocks can be potent long-term value creators. Pharma titans Pfizer and Bristol Myers Squibb sport two of the highest yields within their peer group.
06/18 10:00 EST - businesswire.com
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Inf.
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Inf.
06/18 05:56 EST - seekingalpha.com
Pfizer Stock: The Reversal Should Keep Going
Pfizer's stock initially showed signs of recovery, but then stagnated while the rest of the market continued to grow. However, I expect a recovery in the medium term. The Company's Q1 results showed strong performance in non-COVID products and cost-saving measures, leading to analyst sentiment improvement. The recent Wall Street earnings estimates indicate that the Street expects PFE to bottom out in FY2024 in terms of EPS and that fundamentals will then rebound.
Pfizer Stock: The Reversal Should Keep Going
Pfizer's stock initially showed signs of recovery, but then stagnated while the rest of the market continued to grow. However, I expect a recovery in the medium term. The Company's Q1 results showed strong performance in non-COVID products and cost-saving measures, leading to analyst sentiment improvement. The recent Wall Street earnings estimates indicate that the Street expects PFE to bottom out in FY2024 in terms of EPS and that fundamentals will then rebound.
06/18 05:14 EST - marketwatch.com
Kansas sues Pfizer, saying it misled the public over COVID-19 vaccine
The state of Kansas has filed a lawsuit against Pfizer alleging the company misled the public about the safety and effectiveness of its COVID-19 vaccine including by working to censor critical information on social media.
Kansas sues Pfizer, saying it misled the public over COVID-19 vaccine
The state of Kansas has filed a lawsuit against Pfizer alleging the company misled the public about the safety and effectiveness of its COVID-19 vaccine including by working to censor critical information on social media.
06/18 02:00 EST - youtube.com
Kansas sues Pfizer alleging it ‘misled' the public about safety of COVID vaccine
Kansas Attorney General Kris Kobach says Pfizer ‘violated' the Consumer Protection Act on ‘The Bottom Line.' #foxbusiness #thebottomline
Kansas sues Pfizer alleging it ‘misled' the public about safety of COVID vaccine
Kansas Attorney General Kris Kobach says Pfizer ‘violated' the Consumer Protection Act on ‘The Bottom Line.' #foxbusiness #thebottomline
06/17 17:06 EST - marketwatch.com
Merck's vaccine approval poses threat to one of Pfizer's top-selling products
Merck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.'s top-selling products.
Merck's vaccine approval poses threat to one of Pfizer's top-selling products
Merck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.'s top-selling products.
06/17 16:10 EST - nypost.com
Pfizer sued by Kansas for allegedly hiding COVID vaccine risks, making false claims
The lawsuit claims that, beginning shortly after the vaccine's rollout in early 2021, Pfizer concealed evidence that the shot was linked to pregnancy complications, including miscarriage, as well as inflammation in and around the heart.
Pfizer sued by Kansas for allegedly hiding COVID vaccine risks, making false claims
The lawsuit claims that, beginning shortly after the vaccine's rollout in early 2021, Pfizer concealed evidence that the shot was linked to pregnancy complications, including miscarriage, as well as inflammation in and around the heart.
06/17 14:51 EST - reuters.com
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit
The U.S. state of Kansas on Monday sued Pfizer , accusing the company of misleading the public about its COVID-19 vaccine by hiding risks while making false claims about its effectiveness.
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit
The U.S. state of Kansas on Monday sued Pfizer , accusing the company of misleading the public about its COVID-19 vaccine by hiding risks while making false claims about its effectiveness.
06/17 13:22 EST - benzinga.com
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech SE's BNTX partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech SE's BNTX partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.